Bioscibex secures prestigious Venture Kick phase III award to accelerate its market launch

Bioscibex has reached another major milestone by winning the final stage of the Venture Kick program, receiving CHF 100,000 to accelerate the development of its next-generation single-use bioreactors. This achievement comes shortly after the startup’s recognition in the Top 100 Swiss Startups, where it secured 81st place, further highlighting its strong innovation potential.

Recognition of a promising biotech innovator
Venture Kick is one of Switzerland’s most prestigious philanthropic initiatives, designed to bridge the gap between research and entrepreneurship. Selected startups benefit from financial support, entrepreneurial training, and access to a broad network of experts and investors. By winning Phase III of the program, Bioscibex has now secured full funding support, a testament to the strength of its technology and its promising business trajectory.

Simplifying cell culture with SW1NGO
Founded to tackle one of biomanufacturing’s most critical bottlenecks, Bioscibex is developing breakthrough single-use bioreactors that make cell culture simpler, safer, and more scalable. Its flagship product, SW1NGO, condenses the traditional seven-step cell culture process into just two steps, reducing contamination risks, minimizing manual handling, and lowering capital costs.

Designed for both R&D and industrial manufacturing, SW1NGO operates across a scalable working volume from 30 mL to 30 L, allowing seamless transition from laboratory to production scale. With CHF 1 million in secured funding and strong early interest from leading biopharmaceutical companies, Bioscibex is preparing for its commercial launch in 2026, positioning itself as a transformative player in the Swiss biotech ecosystem.

Winning Venture Kick Phase III not only validates Bioscibex’s technological innovation but also underscores its potential to drive efficiency and safety in biomanufacturing on a global scale.